Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study
September 16 2021 - 8:35AM
Dow Jones News
By Michael Dabaie
Gilead Sciences Inc. said new data showed its treatment Trodelvy
significantly improved quality of life over the standard of care in
2L+ metastatic triple-negative breast cancer.
The company said that in addition to previously reported overall
survival benefit observed with Trodelvy compared with chemotherapy,
this new subanalysis demonstrated significant and clinically
meaningful improvements in health-related quality of life.
Gilead said it presented the results at the European Society of
Medical Oncology Congress 2021. TNBC is the most aggressive type of
breast cancer and accounts for about 15% of all breast cancers,
Gilead said.
"In TNBC, limited treatment options and poor survival outcomes
are compounded by a significant decrease in quality of life,
especially in relapsed or refractory metastatic disease, where
patients can undergo many rounds of chemotherapy," said Sibylle
Loibl of the Center for Hematology and Oncology at
Bethanien-Hospital Frankfurt. "Trodelvy is not only the first
treatment to extend survival in these patients, but this analysis
shows it can also significantly lessen the burden of symptoms when
quality time is especially important," she said.
Gilead also said new data from the Phase 3 Ascent study in
metastatic TNBC showed Trodelvy improved progression-free survival,
overall survival and objective response rate compared with
chemotherapy in patients who weren't initially diagnosed with
TNBC.
"In the metastatic stage of breast cancer, it is not uncommon
for people to change from one subtype to another," said Javier
Cortes, head of the International Breast Cancer Center in Madrid
and Barcelona.
Roughly one-third of patients with TNBC in the study weren't
originally diagnosed with TNBC, and still experienced a survival
benefit with Trodelvy compared with chemotherapy, Gilead said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 16, 2021 08:20 ET (12:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024